Sensitized detection of inhibitory fragments and iterative development of non-peptidic protease inhibitors by dynamic ligation screening

Marco Florian Schmidt, Albert Isidro-Llobet, Michael Lisurek, Adeeb El-Dahshan, Jinzhi Tan, Rolf Hilgenfeld, Jörg Rademann

37 Citations (Scopus)

Abstract

(Chemical Presented) A potential anti-SARS drug has been developed by dynamic ligation screening (DLS), by which nucleophilic fragments are directed to the protein's active site by reversible reaction with an aldehyde inhibitor. Their inhibitory effect is detected by competition with a fluorogenic enzyme substrate. With this concept, low-affinity fragments binding specifically to the active site are quickly identified in a functional enzyme assay.

Original languageEnglish
JournalAngewandte Chemie - International Edition
Volume47
Issue number17
Pages (from-to)3275-3278
Number of pages4
ISSN1433-7851
DOIs
Publication statusPublished - 14.04.2008

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Coronavirus related work

  • Research on SARS-CoV-2 / COVID-19

Fingerprint

Dive into the research topics of 'Sensitized detection of inhibitory fragments and iterative development of non-peptidic protease inhibitors by dynamic ligation screening'. Together they form a unique fingerprint.

Cite this